Skip to main content

Transgenomic Posts Slight Q3 Revenue Increase, Narrows Net Loss

NEW YORK (GenomeWeb News) – Transgenomic today reported a 4 percent increase in third-quarter revenues alongside an improved net loss compared to the year-ago period.
For the quarter ended Sept. 30, Transgenomic's net sales from continuing operations climbed to $5.4 million from $5.2 million during the comparable period of 2007.
R&D spending increased 3 percent to $2.8 million from $2.7 million in the third quarter of 2007, while SG&A spending fell 5 percent to $684,000 from $720,000 year over year.
Transgenomic trimmed its third-quarter net loss by 63 percent, to $499,000, or $.01 per share, from $1.3 million, or $.03 per share, for the third quarter of 2007.
Craig Tuttle, president and CEO of Transgenomic, noted that the quarterly net loss followed two consecutive quarters of profitability. “Historically our third quarter has been slower for our instrument and service businesses due to summer laboratory closures in Europe and heavy vacation schedules in the US,” he said. 
Tuttle added that Transgenomic remains “confident” in its financial performance, and that the company expects to expand its services “as we evaluate in-licensing, collaboration, and acquisition opportunities that have the potential to create additional value and accelerate growth.”
The company’s cash and cash equivalents totaled $4.8 million as of Sept. 30.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.